Investigating evolutionary perspective of carcinogenesis with single-cell transcriptome analysis

Chinese Journal of Cancer

Volumn 32, Issue 12, 2013, Pages 636-639

  Zhang, Xi ^a,c   Zhang, Cheng ^a,c   Li, Zhongjun ^a,c   Zhong, Jiangjian ^b   Weiner, Leslie P ^a   Zhong, Jiang F ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b Z Genetic Medicine LLC   (United States)

^c THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Cancer molecular pathways; Leukemia; Single cell transcriptome

Indexed keywords

BCR ABL PROTEIN; BOSUTINIB; DASATINIB; IMATINIB; NILOTINIB; PROTEIN P53; TRANSCRIPTOME;

ARTICLE; BONE MARROW TRANSPLANTATION; CARCINOGENESIS; CELL HETEROGENEITY; CHRONIC MYELOID LEUKEMIA; CIRCULATING TUMOR CELL; GENE EXPRESSION PROFILING; GENETIC ANALYSIS; HEMATOPOIETIC STEM CELL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LEUKEMIA; NONHUMAN; PHILADELPHIA 1 CHROMOSOME; SINGLE CELL ANALYSIS;

CARCINOGENESIS; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION PROFILING; HEMATOPOIETIC STEM CELLS; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MICROFLUIDIC ANALYTICAL TECHNIQUES; SINGLE-CELL ANALYSIS; TRANSCRIPTOME;

EID: 84888583502     PISSN: 1000467X     EISSN: 1944446X     Source Type: Journal    
DOI: 10.5732/cjc.012.10291     Document Type: Article

References (41)

1. Chen Y, Zhang B, Feng H, et al. An automated microfluidic device for assessment of mammalian cell genetic stability. Lab Chip, 2012,12:3930-3935.
2. Fan JB, Chen J, April CS, et al. Highly parallel genome-wide expression analysis of single mammalian cells. PLoS One, 2012,7:e30794.
3. Zhong JF, Chen Y, Marcus JS, et al. A microfluidic processor for gene expression profiling of single human embryonic stem cells. Lab Chip, 2008, 8:68-74.
4. Li Z, Zhang C, Weiner LP, et al. Molecular characterization of heterogeneous mesenchymal stem cells with single-cell transcriptomes. Biotechnol Adv, 2013,31:312-317.
5. Morris SA, Teo RT, Li H, et al. Origin and formation of the first two distinct cell types of the inner cell mass in the mouse embryo. Proc Nat Acad Sci U S A, 2010,107:6364-6369.
6. Guo G, Huss M, Tong GQ, et al. Resolution of cell fate decisions revealed by single-cell gene expression analysis from zygote to blastocyst. Dev Cell, 2010, 18:675-685.
7. Kurimoto K, Yabuta Y, Ohinata Y, et al. An improved single-cell cDNA amplification method for efficient high-density oligonucleotide microarray analysis. Nucleic Acids Res, 2006, 34:e42.
8. Evsikov AV, Solter D, Evsikov AV, et al. Comment on "'Stemness': transcriptional profiling of embryonic and adult stem cells" and "a stem cell molecular signature". Science, 2003, 302:393.
9. Ramalho-Santos M, Yoon S, Matsuzaki Y, et al. "Stemness": transcriptional profiling of embryonic and adult stem cells. Science, 2002,298:597-600.
10. Ivanova NB, Dimos JT, Schaniel C, et al. A stem cell molecular signature. Science, 2002,298:601-604.
11. Uemura E. Age-related changes in neuronal RNA content in rhesus monkeys (Macaca mulatta). Brain Res Bull, 1980,5:117-119.
12. Chen Y, Zhong JF. Microfluidic devices for high-throughput gene expression profiling of single hESC-derived neural stem cells. Methods Mol Biol, 2008,438:293-303.
13. Zhong JF, Feng Y, Taylor CR. Microfluidic devices for investigating stem cell gene regulation via single-cell analysis. Curr Med Chem, 2008,15:2897-2900.
14. Swanton C. Intratumor heterogeneity: evolution through space and time. Cancer Res, 2012,72:4875-4882.
15. Gerlinger M, Rowan AJ, Horswell S, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med, 2012,366:883-892.
16. Sottoriva A, Spiteri I, Piccirillo SG, et al. Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics. Proc Natl Acad Sci U S A, 2013,110:4009-4014.
17. Zhong JF, Song Y, Du J, et al. Gene regulation networks related to neural differentiation of hESC. Gene Expr, 2007,14:23-34.
18. Li SC, Jin Y, Loudon WG, et al. Increase developmental plasticity of human keratinocytes with gene suppression. Proc Nat Acad Sci U S A, 2011,108:12793-12798.
19. Gunsilius E, Gastl G, Petzer AL. Hematopoietic stem cells. Biomed Pharmacother, 2001, 55:186-194.
20. Brecher G, Cronkite EP. Post-radiation parabiosis and survival in rats. Proc Soc Exp Biol Med, 1951,77:292-294.
21. Lorenz E, Uphoff D, Reid TR, et al. Modification of irradiation injury in mice and guinea pigs by bone marrow injections. J Natl Cancer Inst, 1951, 12:197-201.
22. Thomas ED, Lochte HL, Lu WC, et al. Intravenous infusion of bone marrow in patients receiving radiation and chemotherapy. N Engl J Med, 1957,257:491-496.
23. Bortin MM. A compendium of reported human bone marrow transplants. Transplantation, 1970, 9:571-587.
24. Speck B, Zwaan FE, van Rood JJ, et al. Allogeneic bone marrow transplantation in a patient with aplastic anemia using a phenotypically HL-A-identifcal unrelated donor. Transplantation, 1973,16:24-28.
25. Buchdunger E, Zimmermann J, Mett H, et al. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res, 1996,56:100-104.
26. Druker BJ, Guilhot F, O'Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med, 2006,355:2408-2417.
27. Deininger MWN, O'Brien SG, Ford JM, et al. Practical management of patients with chronic myeloid leukemia receiving imatinib. J Clin Oncol, 2003,21:1637-1647.
28. Hughes TP, Hochhaus A, Branford S, et al. Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS). Blood, 2010,116:3758-3765.
29. Guilhot F, Druker B, Larson RA, et al. High rates of durable response are achieved with imatinib after treatment with interferon alpha plus cytarabine: results from the International Randomized Study of Interferon and STI571 (IRIS) trial. Haematologica, 2009,94:1669-1675.
30. Corbin AS, La Rosee P, Stoffregen EP, et al. Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib. Blood, 2003,101:4611-4614.
31. Graham SM, Jorgensen HG, Allan E, et al. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood, 2002,99:319-325.
32. Kantarjian H, Giles F, Wunderle L, et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med, 2006,354:2542-2551.
33. Hochhaus A, Kantarjian HM, Baccarani M, et al. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood, 2007,109:2303-2309.
34. Sinclair A, Latif AL, Holyoake TL. Targeting survival pathways in chronic myeloid leukaemia stem cells. Br J Pharmacol, 2013 Mar 20. doi: 10.1111/bph.12183. [Epub ahead of print]
35. Jorgensen HG, Allan EK, Jordanides NE, et al. Nilotinib exerts equipotent antiproliferative effects to imatinib and does not induce apoptosis in CD34+ CML cells. Blood, 2007,109:4016-4019.
36. Long B, Zhu H, Zhu C, et al. Activation of the Hedgehog pathway in chronic myelogeneous leukemia patients. J Exp Clin Cancer Res, 2011,30:8.
37. Wang SM, Zhang MQ. Transcriptome study for early hematopoiesis-achievement, challenge and new opportunity. J Cell Physiol, 2010,223:549-552.
38. Seke Etet PF, Vecchio L, Nwabo Kamdje AH. Interactions between bone marrow stromal microenvironment and B-chronic lymphocytic leukemia cells: any role for Notch, Wnt and Hh signaling pathways? Cellular Signal, 2012,24:1433-1443.
39. Peng C, Chen Y, Yang Z, et al. PTEN is a tumor suppressor in CML stem cells and BCR-ABL-induced leukemias in mice. Blood, 2010,115:626-635.
40. Chen Y, Hu Y, Zhang H, et al. Loss of the Alox5 gene impairs leukemia stem cells and prevents chronic myeloid leukemia. Nat Genet, 2009,41:783-792.
41. + ALL patient and reveals FoxO as a theranostic marker. Cancer Biol Ther, 2011, 11:552-558.